A new vaccine could change how doctors fight colon cancer forever

NewsScientists think they’ve found a new way to stop cancer before it startsDr. Stacy Norton receives an experimental Lynch syndrome vaccine during a clinical trial at MD Anderson Cancer Center in Houston as researchers investigate whether immunization can prevent colorectal cancer before tumors develop.Getty ImagesResearchers in the United States and Europe are testing a new generation of vaccines designed to prevent certain forms of colon cancer before tumors develop, offering hope to people with Lynch syndrome, an inherited condition that dramatically increases the risk of colorectal and several other cancers. Scientists believe the vaccines could train the immune system to identify and destroy precancerous cells years before they become life-threatening disease, according to ScienceDaily.Among those watching the research closely is Dr. Stacy Norton, a Houston physician whose family has been heavily affected by cancers linked to Lynch syndrome. After losing relatives to cancer and discovering she carried the inherited mutation herself, Norton volunteered to participate in a clinical trial studying whether a vaccine could reduce the formation of precancerous growths in the colon. Lynch syndrome is caused by inherited defects in DNA repair genes that normally help correct mistakes that occur when cells divide. When those repair mechanisms fail, genetic abnormalities can accumulate and significantly increase the likelihood of colorectal cancer, often at younger ages than seen in the general population. Experts estimate roughly 1 million Americans carry a Lynch-related mutation, many without knowing it. People with Lynch syndrome face a much higher risk of colorectal cancer than the average person. While most individuals have a lifetime colorectal cancer risk of about 5%, some Lynch syndrome carriers may face risks approaching 80% depending on the specific mutation involved. The condition is also associated with elevated risks for endometrial, ovarian, pancreatic, stomach and certain skin cancers. Current prevention efforts rely heavily on frequent screenings, particularly colonoscopies, which can detect and remove precancerous polyps before they become malignant. Many Lynch syndrome patients undergo annual colonoscopies, a far more aggressive screening schedule than that recommended for the general population. Scientists hope vaccines could eventually complement or reduce the burden of that intensive screening process. Unlike vaccines that prevent infections linked to cancer, such as HPV or hepatitis B, the new shots target proteins produced by genetic mutations that accumulate in precancerous cells. Researchers say those abnormal proteins can act as warning signals, allowing the immune system to recognize and attack dangerous cells before tumors form. One experimental vaccine developed by Swiss biotechnology company Nouscom recently completed an early-stage study involving Lynch syndrome carriers at MD Anderson Cancer Center. Researchers reported that the vaccine stimulated immune responses associated with cancer cell destruction and that follow-up colonoscopies showed fewer precancerous lesions and an absence of advanced polyps among participants during the study period. Cancer specialists not involved in the research say the findings are encouraging but caution that larger trials will be needed to determine whether the vaccines can provide durable protection and ultimately reduce cancer diagnoses. Additional studies are planned to better understand how strongly the immune system can be activated and how long vaccine-induced protection may last.Other research groups are pursuing similar approaches. Oxford University researchers have begun preliminary testing of a Lynch syndrome vaccine that uses messenger RNA technology developed by Moderna, while California-based ImmunityBio is studying a separate vaccine candidate designed to target different cancer-related markers. Results from those programs are expected to provide additional evidence about whether preventive cancer vaccines can become a practical option for high-risk patients. The research comes as health officials continue to monitor a rise in colorectal cancer diagnoses among younger adults. Although Lynch syndrome accounts for only a portion of those cases, experts say expanding access to genetic testing may help identify more people who could benefit from heightened screening and, potentially, future preventive treatments. For now, researchers emphasize that routine screenings remain the most effective defense against colorectal cancer. However, scientists say the ongoing vaccine studies represent a promising step toward a future in which people born with inherited cancer risk genes may have additional tools to prevent disease before it begins. ALSO TRENDING: A routine stop turned into an explosive scene at an Arizona gas stationALSO TRENDING: Florida man wasn’t supposed to be on the plane. What happened next stunned workersALSO TRENDING: A judge just blocked New York’s new law. Here’s what it meansChris Pugh covers trending news and national breaking stories, focusing on the moments, conversations, and cultural flashpoints shaping the national news cycle. Chris worked as a digital reporter for...This article was produced with assistance from AI tools and reviewed by AL.com staff.